Back

Evaluating sglt2 inhibitor application in heart failure patients across the spectrum in a large multi-hospital healthcare network

11 May 2026 (16:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (8) Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Ms Ximena Zalazar

Piedmont Heart Institute, Atlanta (United States of America)

5 More presentations in this session

Presentation thumbnail
Evolution of heart failure management in korea: a serial comparison of physician awareness and practice patterns (2019 vs. 2025)
Associate Professor S. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Variation in initial pharmacological therapy for heart failure with reduced ejection fraction: an international case-based survey
Mr H. Amin (Enschede, NL)
Abstract Slides
Presentation thumbnail
Safety of sodium-glucose cotransporter-2 inhibitor in low body mass index patients who have heart failure with reduced ejection fraction
Doctor J. Lee (Hwaseong, KR)
Abstract Slides
Presentation thumbnail
Implementation of guideline-directed pharmacotherapy in hospitalized and outpatient heart failure care: a web-based survey
Professor M. Tokmakova (Plovdiv, BG)
Abstract Slides
Presentation thumbnail
Patient and prescriber knowledge of SGLT2i sick day rules: a single centre cohort study
Doctor B. Woolfenden (Dublin 9, IE)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (8)

The Event

Event poster

Heart Failure 2026

11 May 2026 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Contemporary use of SGLT2i therapy among patients hospitalized for heart failure with reduced ejection fraction in the United States
22 May 2023
thumbnail
Congress Session
Solving the puzzle of heart failure treatment
18 May 2025
thumbnail
Congress Presentation
Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis
27 August 2021
thumbnail
Congress Presentation
SGLT2 Inhibitors in patients with cancers
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources